Key result
Higher CHA2DS2-VASc score in hypertensive patients with sinus rhythm predicts ~112% greater thromboembolic risk.
Why the study?
The CHA2DS2-VASc score is established for thromboembolic risk stratification in NVAF but its prognostic role in arterial hypertension patients with sinus rhythm is unclear.
Does the CHA2DS2-VASc score predict thromboembolic events, cardiovascular hospitalisation, and all-cause death in patients with arterial hypertension and stable sinus rhythm?
Cohort (n=12,599)
Does the CHA2DS2-VASc score predict thromboembolic events, cardiovascular hospitalisation, and all-cause death in patients with arterial hypertension and stable sinus rhythm?
Hazard Ratio: 2.12
p-value: p=<0.0001
The CHA2DS2-VASc score effectively stratifies the risk of thromboembolic events, cardiovascular hospitalization, and death in hypertensive patients in sinus rhythm, with accuracy comparable to its use in atrial fibrillation.
May aid risk stratification in sinus-rhythm hypertension; leaves open whether CHA2DS2-VASc should guide anticoagulation.
The CHA2DS2-VASc score well stratifies the risk for thromboembolic events in non-valvular atrial fibrillation (NVAF) patients. This score may also predict thromboembolic events in sinus rhythm populations. The purpose of this study was to assess the prognostic role of CHA2DS2-VASc in a Caucasian community population of patients with arterial hypertension and sinus rhythm. A total of 12,599 arterial hypertension residents not receiving anticoagulation were selected from a community population in Trieste between November 2009 and October 2014: 11,159 sinus rhythm and 1440 NVAF patients. We considered thromboembolic events, cardiovascular hospitalisation and all-cause death in all patients divided according to CHA2DS2-VASc. Sinus rhythm patients were 74 (interquartile range 65–81) years old, 50% were women, 32% with CAD, mean CHA2DS2-VASc 3.68 ± 1.47 points, significantly lower than NVAF patients (4.26 ± 1.50, P < 0.001). After 37 months follow-up, an increasing CHA2DS2-VASc corresponded to a higher rate of thromboembolic events in sinus rhythm patients, ranging from 0% in patients with a score of 1 or 2 to 2.6% in those with a score of 6 or greater (P < 0.0001). A similar trend was found in the reference NVAF group. At Cox multivariable analysis, CHA2DS2-VASc predicted thromboembolic events (hazard ratio (HR) 2.12), cardiovascular hospitalisation (HR 1.55) and all-cause death (HR 1.57). The predictive accuracy of CHA2DS2-VASc was similar in sinus rhythm and NVAF patients for thromboembolic events, cardiovascular hospitalisation and all-cause death (area under the curve statistic 0.76 vs. 0.76, 0.68 vs. 0.66, 0.64 vs. 0.64, respectively). In a community population of Caucasian arterial hypertension patients in sinus rhythm, CHA2DS2-VASc rather well stratifies for adverse clinical events at mid-term follow-up with a similar accuracy to NVAF patients. These results might be clinically relevant in this setting of sinus rhythm patients.
No takes yet. Share an insight, caveat, or question.
Mazzone et al. (2017) conducted a cohort in Arterial hypertension and stable sinus rhythm (n=12,599). CHA2DS2-VASc score vs. Lower CHA2DS2-VASc score was evaluated on Thromboembolic events (HR 2.12, p=<0.0001). In patients with arterial hypertension and sinus rhythm, a higher CHA2DS2-VASc score predicted thromboembolic events (HR 2.12), cardiovascular hospitalization, and all-cause death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: